Literature DB >> 1899875

Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent.

H W Murray1, A M Granger, S K Mohanty.   

Abstract

The capacity of Leishmania donovani-infected BALB/c mice to respond to conventional chemotherapy with pentavalent antimony (Sb) is T cell dependent and, in nude mice, can be restored in part by treatment with the T cell lymphokines, interferon-gamma (IFN-gamma) or interleukin-2 (IL-2). To document the presumed role of endogenous IFN-gamma and IL-2 in responsiveness to antileishmanial chemotherapy in the T cell-intact host, L. donovani-infected euthymic BALB/c mice were treated with anti-IFN-gamma or anti-IL-2 monoclonal antibodies (MAbs) before and after Sb administration. Treatment with MAbs exacerbated visceral infection but did not inhibit the in vivo efficacy of Sb. Thus, while combination therapy of Sb plus IFN-gamma or IL-2 may prove beneficial in T cell-deficient hosts with visceral leishmaniasis, T cell activities other than or in addition to IFN-gamma or IL-2 production may mediate in vivo responsiveness to antileishmanial chemotherapy in the euthymic host.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899875     DOI: 10.1093/infdis/163.3.622

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 3.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.

Authors:  Levi Eduardo Soares Reis; Rory Cristiane Fortes de Brito; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Rodrigo Dian Oliveira Aguiar Soares; Claudia Martins Carneiro; Paula Melo de Abreu Vieira; Guilherme Santos Ramos; Frédéric Jean Georges Frézard; Bruno Mendes Roatt; Alexandre Barbosa Reis
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

Authors:  H W Murray; S Delph-Etienne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

7.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.